Share Price Change Share Volume
Open: Day Range: Prev Close:
Market Date: 22 May 2020

Share Trade Detail

Share Trade Value (RM)
Share VWAP (RM)
4 Weeks Price Range
4 Weeks Share Change (%)
Share Avg Volume (4 Weeks)
1 Year Price Range
1 Year Share Change (%)
Share Avg Volume (1 Year)

Market Capital (RM)
EPS (cent)
P/E Ratio
ROE (%)
Profit Margin (%)
CAGR - Revenue (%)
CAGR - PAT (%)
Number of Share
Dividend (cent)
Dividend Yield (%)
Dividend Policy (%)
P/B Ratio
YoY Score

* Calculated based on the net profit of the trailing twelve months and latest number of shares issued.

No. Financial
PBT (RM,000)Net Profit
EPS (Cent)Dividend
19 May 202031 Dec 2020131 Mar 2020819,92130,88022,3998.576.001.340 Malaysia Stock - KLSE Quarter Report History
20 Feb 202031 Dec 2019431 Dec 2019715,683-238,474-178,598-68.450.001.290 Malaysia Stock - KLSE Quarter Report History
20 Nov 201931 Dec 2019330 Sep 2019716,8493,8854810.180.001.980 Malaysia Stock - KLSE Quarter Report History
23 Aug 201931 Dec 2019230 Jun 2019601,89012,4819,2813.562.501.990 Malaysia Stock - KLSE Quarter Report History
16 May 201931 Dec 2019131 Mar 2019786,10830,24319,6177.536.002.030 Malaysia Stock - KLSE Quarter Report History
21 Feb 201931 Dec 2018431 Dec 2018596,64411,9404,4371.712.001.960 Malaysia Stock - KLSE Quarter Report History
19 Nov 201831 Dec 2018330 Sep 2018587,66017,60315,0515.795.002.010 Malaysia Stock - KLSE Quarter Report History
17 Aug 201831 Dec 2018230 Jun 2018582,72911,9705,3942.084.002.000 Malaysia Stock - KLSE Quarter Report History
16 May 201831 Dec 2018131 Mar 2018617,92328,70717,5866.775.002.020 Malaysia Stock - KLSE Quarter Report History
27 Feb 201831 Dec 2017431 Dec 2017613,19619,86621,7008.366.002.030 Malaysia Stock - KLSE Quarter Report History
15 Nov 201731 Dec 2017330 Sep 2017574,50315,2713,5801.385.002.050 Malaysia Stock - KLSE Quarter Report History
16 Aug 201731 Dec 2017230 Jun 2017517,96710,1509,5203.674.002.090 Malaysia Stock - KLSE Quarter Report History

Entitlement TypeDividend
19 May 202031 Dec 202004 Jun 202005 Jun 202030 Jun 2020Interim Dividend6.00000.00 Malaysia Stock -  Dividend
23 Aug 201931 Dec 201911 Sep 201912 Sep 201911 Oct 2019Second interim Dividend2.50000.00 Malaysia Stock -  Dividend
16 May 201931 Dec 201903 Jun 201904 Jun 201927 Jun 2019First Interim Dividend6.00000.00 Malaysia Stock -  Dividend
21 Feb 201931 Dec 201808 Mar 201912 Mar 201910 Apr 2019Interim Dividend2.00000.00 Malaysia Stock -  Dividend
19 Nov 201831 Dec 201803 Dec 201805 Dec 201803 Jan 2019Interim Dividend5.00000.00 Malaysia Stock -  Dividend
17 Aug 201831 Dec 201803 Sep 201805 Sep 201818 Sep 2018Second interim Dividend4.00000.00 Malaysia Stock -  Dividend
16 May 201831 Dec 201830 May 201801 Jun 201820 Jun 2018First Interim Dividend5.00000.00 Malaysia Stock -  Dividend
27 Feb 201831 Dec 201713 Mar 201815 Mar 201828 Mar 2018Interim Dividend6.00000.00 Malaysia Stock -  Dividend
15 Nov 201731 Dec 201729 Nov 201704 Dec 201715 Dec 2017Interim Dividend5.00000.00 Malaysia Stock -  Dividend
01 Sep 201731 Dec 201729 Aug 201705 Sep 201718 Sep 2017Interim Dividend4.00000.00 Malaysia Stock -  Dividend
16 May 201731 Dec 201729 May 201731 May 201707 Jun 2017Interim Dividend4.00000.00 Malaysia Stock -  Dividend
21 Feb 201731 Dec 201607 Mar 201709 Mar 201717 Mar 2017Interim Dividend3.00000.00 Malaysia Stock -  Dividend

TypeRatioRight Issue
20 May 201331 May 201304 Jun 201304 Jun 2013Bonus Issue1 : 100.000 Malaysia Stock -  Bonus/Rights Issue
20 May 201331 May 201304 Jun 201304 Jun 2013Others2 : 10.000 Malaysia Stock -  Bonus/Rights Issue
31 Jan 201215 Feb 201217 Feb 201217 Feb 2012Bonus Issue1 : 100.000 Malaysia Stock -  Bonus/Rights Issue

Member Star
Posts: 107
Joined: Dec 2011
Female, MYS
16 Mar 2012, 08:22 PMPost #1
Pharmaniaga to expand in MidEast, SE Asia
Published: 2012/03/16

Malaysia’s largest local pharmaceutical firm, Pharmaniaga Bhd plans to expand its market in the Middle East and Southeast Asia, particularly, Saudi Arabia, Indonesia, Myanmar and Vietnam.

Chairman Tan Sri Lodin Wok Kamaruddin said the company is looking for growth opportunities in these countries including through mergers and acquisitions.

“We are exploring opportunities in Saudi Arabia as it is a growing market. There is also potential for us to expand in neighbouring countries such as Indonesia, Vietnam and Myanmar. We already have a presence in a few Southeast Asian countries through joint ventures or collaborations but we want to do much more, ” Lodin told Bernama in an interview.

He said there is room for Pharmaniaga to grow but the group's plan is to focus on improving delivery, which requires the company to expand the list of drugs that it is currently supplying to customers.

“We believe we can do more. We have to improve on the delivery of the supply to meet the requirements of the markets,” Lodin said.

According to Lodin, one of the ways to expand its product portfolio is by growing its halal drugs and herbal medicines.
He also said that Pharmaniaga has been performing very well since it was taken over by Boustead Holdings Bhd and with the new management team in place.

He noted that Pharmaniaga’s acquisition of a 51 per cent stake in Idaman Pharma Manufacturing would see improvement in costs, resulting from the streamlining and optimising of manufacturing facilities and production capacities.

Pharmaniaga has also secured a 10-year concession agreement with the Health Ministry to supply drugs and medical items to 3,517 government hospitals and clinics nationwide beginning December 2009. It was reported that the contract was worth RM900 million a year.

For the financial year ended Dec 31 2011, Pharmaniaga’s net profit surged 65.1 per cent to RM52.16 million from RM30.38 million a year ago.

Lodin also said that Pharmaniaga is in the process of meeting the 25 percent public shareholding spread as required by Bursa Malaysia.

“We are still a little bit short, around of 7-8 per cent to meet the required 25 percent. We hope to meet the 25 per cent before April or May,” Lodin said.

He noted that Boustead, recently, had improved the public shareholding spread in Pharmaniaga from two per cent at the completion of its general offer to 17 per cent currently.

He said Boustead, which acquired Pharmaniaga in 2010, might further pare down its shareholding in the pharmaceutical company to meet the 25 per cent public spread.

As at February 20 this year, Boustead holds a 72.36 per cent stake in Pharmaniaga. -- Bernama
Member Star
Posts: 8
Joined: Mar 2016
Female, MYS
01 Apr 2016, 07:55 AMPost #2
PHARMA AGM 2016 story -
Member Star
Posts: 23
Joined: Dec 2018
Male, MYS
22 Feb 2019, 10:16 AMPost #3

Pharmaniaga: 4Q net profit plunges 80%, declares lower dividend. Pharmaniaga 4Q net profit plunged 80% to RM4.44m, from RM21.7m a year ago, mainly due to lower demand coupled with higher finance costs. EPS for the quarter ended Dec 31, 2018 fell to 1.71sen from 8.36sen previously. Revenue was also lower by 3% at RM596.64m compared with RM613.2m a year ago. (The Edge)

Member Star
Posts: 13
Joined: Dec 2018
Male, MYS
22 Feb 2019, 10:20 AMPost #4

FY18 core PATAMI of RM57.4m (+3.6% YoY) came in below expectations at 84%/89% of our/consensus full-year forecasts. The negative variance from our forecast was due to lower-than-expected volumes sales, which prompted us downgrade our FY19E/FY20E forecasts by 18%/22%. TP is cut from RM2.90 to RM2.50 based on an unchanged 11.5x FY19E EPS (-1.5SD below 5-year historical forward mean). Reiterate MP

Member Star
Posts: 13
Joined: Dec 2018
Male, MYS
22 Feb 2019, 10:20 AMPost #5

FY18 core PATAMI of RM57.4m (+3.6% YoY) came in below expectations at 84%/89% of our/consensus full-year forecasts. The negative variance from our forecast was due to lower-thanexpected volumes sales. A fourth interim DPS of 2.0 sen was declared, bringing 12M18 DPS to 16.0 sen, below our expectations. As such we cut our FY19E/FY20E DPS to 14.0 sen from 19.0 sen.

Member Star
Posts: 13
Joined: Dec 2018
Male, MYS
22 Feb 2019, 10:21 AMPost #6

Results’ highlights. QoQ, 4Q18 Core PATAMI fell 72%, excluding the provision for, and write-back and write-off of: (i) receivables (RM6.1m) and (ii) inventories (RM6.6m), respectively, in 4QFY18 and provision for write-off of: (i) receivables (RM1.4m) and (ii) inventories (RM2.2m) in 3QFY18; dragged down by losses at the Logistics and Manufacturing divisions, and exacerbated by a higher effective tax rate of 62% compared to 13% in 3Q18. The Logistics and Distribution Division recorded a pre-tax loss of RM0.4m compared to a pre-tax profit of RM3.7m in 3Q18 due to higher operating expenses, including selling and distribution. Similarly, the manufacturing division’s pre-tax profit fell 29% to RM11m.

YoY, FY18 revenue rose 3% due to increased orders from concession business and government hospitals. Correspondingly, FY18 core PATAMI rose 3.6%, excluding the provision for writeback and write-off of: (i) receivables (RM2.1m) and (ii) inventories (RM17.1m) in FY18 and excluding one-off gains from of RM8m as compensation received in relation to a previously owned JV in China and provisions for receivables and inventories (RM9.5m) in FY17; thanks to better performance from the Logistics and Distribution division and more than offset lower contribution from manufacturing. The Logistics and Distribution division’s FY18 PBT rose two-fold to RM12m attributable to stronger contributions from Government and concession businesses notwithstanding the impact from lower operating expenses. The Manufacturing Division posted a lower PBT, by 19%, due to lower orders from the concession business.

Outlook. The stock has been de-rated on concerns of Government reviewing all medical supplies concession agreements of which Pharmaniaga has a 10-year contract ending in November 2019. We are unsure of the renewability of the contract but Pharmaniaga has the track record, platform and systems already in place for the distributions of such medical supplies. Overseas, the Indonesian operation remains a key area of growth, while further progress is being made in the European Union as the Group seeks to expand its global presence. Over the longer term, we expect its manufacturing division to propel earnings growth. The group aims to add about 200 new products over the next 10 years to its existing portfolio of around 500 products.

Downgrade FY19E/FY20E net profit by 18%/22% to take into account the lower-than-expected sales.

Maintain MP. TP is cut from RM2.90 to RM2.50 based on an unchanged 11.5x FY19E EPS (-1.5SD below 5-year historical forward mean). Key downside risk is the uncertainty regarding the renewal of the government concession which is expected to expire in 2019.

Mark Tse
Member Star
Posts: 16
Joined: Dec 2018
Male, MYS
22 Feb 2019, 10:23 AMPost #7

FY18 earnings dropped by -21.2%yoy to RM42.5m. Pharmaniaga’s full financial year FY18 earnings came in at RM42.5m which is below ours and consensus earnings estimates at 70.4% and 65.8% respectively. The FY18 revenue for the rose modestly by +2.6%yoy while earnings dropped by -21.2%yoy.

Commendable revenue growth. Pharmaniaga’s FY18 higher revenue of RM2,385.0m (from RM2,324.0m in FY17) was mainly due to the higher revenue contribution coming from the logistics and distribution (L&D) division. The L&D segment revenue contribution rose by +6.3%yoy mainly attributable to the contribution from the concession business. This was partially mitigated by lower revenue from its Indonesian division which dipped by -5.4%yoy in view of the depreciation of the Malaysian Ringgit against the Indonesian Rupiah.

Earnings dropped due to a higher finance and tax costs. Pharmaniaga recorded a dropped in FY18 earnings of -42.5%yoy mainly driven by a higher cost incurred in relation to: (i) finance costs (+25.3%yoy) and; (ii) tax costs (+49.1%yoy). The latter was caused by a drawdown of about RM200.0m in borrowing (+51.8%yoy) while the latter was due to the underprovision of tax for prior years of about RM5.6m. In addition, a one-off compensation of about RM7.0m in relation to a previous joint venture company in China was also included in FY17. Nonetheless, these were mitigated by the fall in operating expenses of -10.2%yoy driven by the L&D division which reflects its efficiency in distributing pharmaceutical products to public hospitals in clinics in Malaysia.

Final dividend declared. Pharmaniaga declared a final dividend of 2.0sen per share for the quarter under review. This brings its accumulated dividend for the year to 16.0sen (vs FY17 of 19.0sen).

Member Star
Posts: 63
Joined: Jan 2017
Male, MYS
27 Feb 2019, 12:31 AMPost #8

PHARMA (7081) - Technical & Fundamental Analysis

February 27, 2019 | HONG WEI GIET

Technical Analysis


- PHARMA hit highest shares price RM6.490 on April 23, 2015. Ironically, it dropped by 63% and reached RM2.530 on Feb 26,2016.

- After PHARMA announced further reduction of net profit with 80% (YoY) on 21.2.2019, significant selling pressure with high volume which further pushed PHARMA share price to lowest and hit RM2.610 (Closing price on 22.2.2019)

- There is no sign of recovery in shares price movement.

- PHARMA completed symmetric triangle 


Member Star
Posts: 4
Joined: Feb 2019
Male, MYS
28 Feb 2019, 04:13 PMPost #9

What happened to this counter?No bad news but keep dropping...Why? So dissapdisapp..

Member Star
Posts: 63
Joined: Jan 2017
Male, MYS
07 Apr 2019, 10:28 PMPost #10

PHARMA (7081) - Technical Analysis Follow Up

March 4, 2019 | HONG WEI GIET

Member Star
Posts: 295
Joined: May 2017
Male, MYS
07 Apr 2019, 11:27 PMPost #11

This chart pattern I may have experience.Pharmaniaga downturn not over.Government either wanted to break-up the monopoly of Wht pharma business hold or reduction in price before any new agreement being agree.May put target price rm 1.30-rm 1.45(best case scenario) or cancel the whole license to put pharma below rm 1.00(worst case scenario.

Member Star
Posts: 202
Joined: Mar 2019
Male, MYS
16 May 2019, 01:44 PMPost #12

Day 73 of Fundamental Daily, YAPSS will be covering Pharmaniaga Berhad's fundamental via a short animated video. I hope it helps and please enjoy the video, see ya! #YAPSS #FundamentalDaily #PharmaniagaBerhad

Click the on the link to find out more:

Member Star
Posts: 190
Joined: Sep 2012
Male, MYS
18 May 2019, 10:24 AMPost #13

sign of recovery, Last close $2.49

Member Star
Posts: 63
Joined: Jan 2017
Male, MYS
08 Dec 2019, 06:43 PMPost #14

PHARMA (7081) - Technical and Fundamental Analysis

Technical Analysis


- PHARMA shares price was very volatile and we believe that it was a miss-match between market expectation and company performance.

- On Oct 15, 2019, there is a strong reversal pattern in PHARMA shares price without any positive news. There is always got "People" who know the fact and prepare to speculate shares price to rob small investors' hard-earned money.

- Within a month, PHARMA announced that it is extending its services for the provision of medicines and medical supplies to MOH facilities and secured a five (5) year contract to continue providing logistics and distribution services for MOH.

- We should always remind ourselves and do our own homework to buy-sell any shares in the realistic market. There is no mercy and professional investor in the capital market. Only Winner and Losser!

- PHARMA shares price still continues


Member Star
Posts: 63
Joined: Jan 2017
Male, MYS
08 Dec 2019, 06:44 PMPost #15

PHARMA (7081) - 技术和基本面分析



- PHARMA的股价近期非常波动,因为这与市场预期和公司业绩不符。

- 2019年10月15日,PHARMA股价出现强势逆转然而市场没有任何利好消息。这说明总会有“人”知道事实,并准备投机PHARMA以抢夺小投资者的血汗钱。

- 在一个月内,PHARMA宣布将扩大其向卫生部设施提供药品和医疗用品的服务,并获得了五(5)年的合同,继续为卫生部提供物流和分销服务。

- 我们应时刻提醒自己,并做足够功课。资本市场上没有仁慈和专业的投资者。只有赢家和输家!

- PHARMA的股价自2015年4月28日



Member Star
Posts: 144
Joined: Aug 2015
Male, MYS
13 Apr 2020, 12:18 PMPost #16

Industry Comparision Pharmaceuticals:

  3. KOTRA

yeah doh drool lol mad notworthy question rant rolleyes sad shutup shy smile star sweat thumbup wub cry

P/E Ratio DY ROE PM YoY Score ?